Metastasis suppressor proteins: Discovery, molecular mechanisms, and clinical application

Clinical Cancer Research

Volumn 12, Issue 13, 2006, Pages 3882-3889

  Rinker Schaeffer, Carrie W ^a   O'Keefe, James P ^a   Welch, Danny R ^b   Theodorescu, Dan ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; CASPASE 8; CLAUDIN 1; CLAUDIN 4; CONNECTIVE TISSUE GROWTH FACTOR; CYTOSKELETON PROTEIN; GELSOLIN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE KINASE 7; NERVE CELL ADHESION MOLECULE; NUCLEOSIDE DIPHOSPHATE KINASE A; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PROTEIN BRMS1; PROTEIN CADHERIN 11; PROTEIN CD44; PROTEIN CRSP3; PROTEIN DRG 1; PROTEIN KISS1; PROTEIN RECK; PROTEIN RHOGD12; REPRESSOR PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; UVOMORULIN;

CANCER RESEARCH; CARCINOGENESIS; CLINICAL TRIAL; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; METASTASIS; METASTASIS INHIBITION; MOLECULAR MECHANICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SUPPRESSOR GENE;

ANIMALS; HUMANS; MODELS, IMMUNOLOGICAL; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 33746088024     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1014     Document Type: Review

References (96)

1. Steeg PS, Cohn KH, Leone A. Tumor metastasis and nm23: current concepts. Cancer Cell 1991;3:257-62.
2. Steeg PS, Bevilacqua G, Kopper L, et al. Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst 1988;80:200-4.
3. Kauffman EC, Robinson VL, Stadler WM, Sokoloff MH, Rinker-Schaeffer CW. Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site [comment]. J Urol 2003;169:1122-33.
4. Shevde LA, Welch DR. Metastasis suppressor pathways-an evolving paradigm. Cancer Lett 2003;198:1-20.
5. Steeg PS. Metastasis suppressors alter the signal transduction of cancer cells. Nat Rev Cancer 2003;3:55-63.
6. Robinson VL, Kauffman EC, Sokoloff MH, Rinker-Schaeffer CW. The basic biology of metastasis. Cancer Treat Res 2004;118:1-21.
7. Leone A, Flatow U, King CR, et al. Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell 1991;65:25-35.
8. Yoshida BA, Dubauskas Z, Chekmareva MA, Christiano TR, Stadler WM, Rinker-Schaeffer CW. Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res 1999;59:5483-7.
9. 2-terminal kinase kinases JNKK1/MKK4 and MKK7. Cancer Res 2005;65:10984-91.
10. Xia W, Unger P, Miller L, Nelson J, Gelman IH. The Src-suppressed C kinase substrate, SSeCKS, is a potential metastasis inhibitor in prostate cancer. Cancer Res 2001;61:5644-51.
11. Goldberg SF, Miele ME, Hatta N, et al. Melanoma metastasis suppression by chromosome 6: evidence for a pathway regulated by CRSP3 and TXNIP. Cancer Res 2003;63:432-40.
12. Hickson JA, Huo D, Vander Griend DJ, Lin A, Rinker-Schaeffer CW, Yamada SD. The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res 2006;66:2264-70.
13. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72.
14. Dong JT, Lamb PW, Rinker-Schaeffer CW, et al. KAU, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2. Science 1995;268:884-6.
15. Yin HL, Stossel TP. Control of cytoplasmic actin gelsol transformation by gelsolin, a calcium-dependent regulatory protein. Nature 1979;281:583-6.
16. Shimizu K, Kaibuchi K, Nonaka H, Yamamoto J, Takai Y. Tissue and subcellular distributions of an inhibitory GDP/GTP exchange protein (GDI) for the rho proteins by use of its specific antibody. Biochem Biophys Res Commun 1991;175:199-206.
17. Boiler K, Vestweber D, Kemler R. Cell-adhesion molecule uvomorulin is localized in the intermediate junctions of adult intestinal epithelial cells. J Cell Biol 1985;100:327-32.
18. Girgrah N, Ackerley CA, Moscarello MA. Localization of CD44 (P80) on the external surface of a human astrocytoma cell. Neuroreport 1991;2:441-4.
19. Nash KT, Welch DR. The KISS1 metastasis suppressor: mechanistic insights and clinical utility. Front Biosci 2006;11:647-59.
20. Yeung K, Seitz T, Li S, et al. Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 1999;401:173-7.
21. Bosnar MH, De Gunzburg J, Bago R, Brecevic L, Weber I, Pavelic J. Subcellular localization of A and B Nm23/NDPK subunits. Exp Cell Res 2004;298:275-84.
22. Lin M, van Golen KL. Rho-regulatory proteins in breast cancer cell motility and invasion. Breast Cancer Res Treat 2004;84:49-60.
23. Gildea JJ, Seraj MJ, Oxford G, et al. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 2002;62:6418-23.
24. Fujita H, Okada F, Hamada J, et al. Gelsolin functions as a metastasis suppressor in B16-BL6 mouse melanoma cells and requirement of the carboxyl-terminus for its effect. Int J Cancer 2001;93:773-80.
25. DerMardirossian C, Bokoch GM. GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol 2005;15:356-63.
26. Gelman IH, Gao L. SSeCKS/Gravin/AKAP12 metastasis suppressor inhibits podosome formation via RhoA- and Cdc42-dependent pathways. Mol Cancer Res 2006;4:151-8.
27. Hakem A, Sanchez-Sweatman O, You-Ten A, et al. RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev 2005;19:1974-9.
28. Itoh K, Yoshioka K, Akedo H, Uehata M, Ishizaki T, Narumiya S. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 1999;5:221-5.
29. Titus B, Frierson HF, Jr., Conaway M, et al. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Res 2005;65:7320-7.
30. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-6.
31. Chellaiah M, Kizer N, Silva M, Alvarez U, Kwiatkowski D, Hruska KA. Gelsolin deficiency blocks podosome assembly and produces increased bone mass and strength. J Cell Biol 2000;148:665-78.
32. Moussad EE, Brigstock DR. Connective tissue growth factor: what's in a name? Mol Genet Metab 2000;71:276-92.
33. Chang CC, Shin JY, Jeng YM, et al. Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. J Natl Cancer Inst 2004;96:364-75.
34. Liu WM, Zhang XA. KAI1/CD82, a tumor metastasis suppressor. Cancer Lett, 2005. Available from http://www.doi:10.1016/j. Canlet.2005.08.018.
35. Sridhar SC, Miranti CK. Tetraspanin KAI1/CD82 suppresses invasion by inhibiting integrin-dependent crosstalk with c-Met receptor and Src kinases. Oncogene 2006;25:2367-78.
36. Stupack DG, Teitz T, Potter MD, et al. Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 2006;439:95-9.
37. Stupack DG, Puente XS, Boutsaboualoy S, Storgard CM, Cheresh DA. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J Cell Biol 2001;155:459-70.
38. Zhao H, Ross FP, Teitelbaum SL. Unoccupied α(v)β3 integrin regulates osteoclast apoptosis by transmitting a positive death signal. Mol Endocrinol 2005;19:771-80.
39. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol 2001;2:285-93.
40. Michl P, Barth C, Buchholz M, et al. Claudin-4 expression decreases invasiveness and metastatic potential of pancreatic cancer. Cancer Res 2003;63:6265-71.
41. Howe KL, Reardon C, Wang A, Nazli A, McKay DM. Transforming growth factor-β regulation of epithelial tight junction proteins enhances barrier function and blocks enterohemorrhagic Escherichia coli O157:H7-induced increased permeability. Am J Pathol 2005;167:1587-97.
42. Noda M, Oh J, Takahashi R, Kondo S, Kitayama H, Takahashi C. RECK: a novel suppressor of malignancy linking oncogenic signaling to extracellular matrix remodeling. Cancer Metastasis Rev 2003;22:167-75.
43. Gao AC, Lou W, Dong JT, Isaacs JT. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 1997;57:846-9.
44. Gao AC, Lou W, Sleeman JP, Isaacs JT. Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate. Cancer Res 1998;58:2350-2.
45. Sleeman J, Moll J, Sherman L, et al. The role of CD44 splice variants in human metastatic cancer. Ciba Found Symp 1995;189:142-51; discussion 151-46, 174-46.
46. Ponta H, Sleeman J, Dall P, Moll J, Sherman L, Herrlich P. CD44 isoforms in metastatic cancer. Invasion Metastasis 1994;14:82-6.
47. Tkach T, Li E, Bestagno M, Burrone OR. Expression of CD44 splice variants in metastatic and non-metastatic mouse tumour cell lines. Immunol Lett 1996;52:81-7.
48. McGary EC, Lev DC, Bar-Eli M. Cellular adhesion pathways and metastatic potential of human melanoma. Cancer Biol Ther 2002;1:459-65.
49. Kashima T, Nakamura K, Kawaguchi J, et al. Overexpression of cadherins suppresses pulmonary metastasis of osteosarcoma in vivo. Int J Cancer 2003;104:147-54.
50. Suyama K, Shapiro I, Guttman M, Hazan RB. A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell 2002;2:301-14.
51. Feltes CM, Kudo A, Blaschuk O, Byers SW. An alternatively spliced cadherin-11 enhances human breast cancer cell invasion. Cancer Res 2002;62:6688-97.
52. Qi J, Chen N, Wang J, Siu CH. Transendothelial migration of melanoma cells involves N-cadherin-mediated adhesion and activation of the p-catenin signaling pathway. Mol Biol Cell 2005;16:4386-97.
53. Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res 2001;61:3819-25.
54. Kyriakis JM, Banerjee P, Nikolakaki E, et al. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 1994;369:156-60.
55. Vander Griend DJ, Kocherginsky M, Hickson J, Stadler W, Lin A, Rinker-Schaeffer C. Suppression of Metastatic Colonization by the Context-Dependent Activation of the JNK Kinases JNKK1/MKK4 and MKK7. Cancer Res 2005;65:10984-91.
56. Yamada SD, Hickson JA, Hrobowski Y, et al. Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res 2002;62:6717-23.
57. Cheng GC, Schulze PC, Lee RT, Sylvan J, Zetter BR, Huang H. Oxidative stress and thioredoxin-interacting protein promote intravasation of melanoma cells. Exp Cell Res 2004;300:297-307.
58. Finkel T. Neutrophils with a license to kill: permeabilized, not stirred. Dev Cell 2003;4:146-8.
59. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001;81:807-69.
60. Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153-83.
61. Morrison DK. KSR: a MAPK scaffold of the Ras pathway? J Cell Sci 2001;114:1609-12.
62. Lozano J, Xing R, Cai Z, et al. Deficiency of kinase suppressor of Ras1 prevents oncogenic ras signaling in mice. Cancer Res 2003;63:4232-8.
63. Fu Z, Smith PC, Zhang L, et al. Effects of Raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. J Natl Cancer Inst 2003;95:878-89.
64. Yeung K, Janosch P, McFerran B, et al. Mechanism of suppression of the Raf/MEK/extracellular signal-regulated kinase pathway by the Raf kinase inhibitor protein. Mol Cell Biol 2000;20:3079-85.
65. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005;4:988-1004.
66. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004;22:2954-63.
67. Shevde LA, Samant RS, Goldberg SF, et al. Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Exp Cell Res 2002;273:229-39.
68. Zhang S, Lin QD, Di W. Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1. Int J Gynecol Cancer 2006;16:522-31.
69. Bandyopadhyay S, Pai SK, Hirota S, et al. PTEN upregulates the tumor metastasis suppressor gene Drg-1 in prostate and breast cancer. Cancer Res 2004;64:7655-60.
70. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666-75.
71. Pomper MG. Translational molecular imaging for cancer. Cancer Imaging 2005;5 Spec No A:S16-26.
72. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006;24:778-89.
73. Rennebeck G, Martelli M, Kyprianou N. Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis? Cancer Res 2005;65:11230-5.
74. Kopfstein L, Christofori G. Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cell Mol Life Sci 2006;63:449-68.
75. Steeg PS, Bevilacqua G, Pozzatti R, Liotta LA, Sobel ME. Altered expression of NM23, a gene associated with low tumor metastatic potential, during adenovirus 2 Ela inhibition of experimental metastasis. Cancer Res 1988;48:6550-4.
76. Li J, Zhou J, Chen G, et al. Inhibition of ovarian cancer metastasis by adeno-associated virus-mediated gene transfer of nm23H1 in an orthotopic implantation model. Cancer Gene Ther 2006;13:266-72.
77. Williams DA, Baum C. Medicine. Gene therapy-new challenges ahead. Science 2003;302:400-1.
78. Chuah M. Challenges in advancing the field of gene therapy-American Society of Gene Therapy Stakeholders' Meeting. A critical review of the science, medicine and regulation. IDrugs 2005;8:483-6.
79. Liu LT, Chang HC, Chiang LC, Hung WC. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 2003;63:3069-72.
80. Jiang W, Hiscox S, Bryce R, Horrobin D, Mansel R. The effects of n-6 polyunsaturated fatty acids on the expression of nm-23 in human cancer cells. Br J Cancer 1988;77:731-8.
81. Ouatas T, Clare S, Hartsough M, DeLaRosa A, Steeg P. MMTV-associated transcription factor binding sites increase nm23-1 metastasis suppressor gene expression in human breast carcinoma cell lines. Clin Exp Metastasis 2002;19:35-42.
82. Ouatas T, Halverson D, Steeg P. Dexamethasone and medroxyprogesterone acetate elevate Nm23-1 metastasis suppressor expression in metastatic human breast carcinoma cells: new uses for old compounds. Clin Cancer Res 2003;9:3763-72.
83. Zaucha R, Sosinska-Mielcarek K, Jassem J. Long-term survival of a patient with primarily chemo-resistant metastatic breast cancer treated with medroxyprogesterone acetate. Breast 2004;13:321-4.
84. Focan C, Beauduin M, Majois F, et al. High-dose oral medroxyprogesterone acetate or tamoxifen as adjuvant hormone therapy for node-negative early-stage breast cancer: randomized trial with 7-year update. Clin Breast Cancer 2004;5:136-41.
85. Palmieri D, Halverson D, Ouatas T, et al. Medroxyprogesterone acetate elevation of Nm23-1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst 2005;97:632-42.
86. Gildea J, Seraj M, Oxford G, et al. RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 2002;62:6418-23.
87. Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM, Frierson HF, Jr. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res 2004;10:3800-6.
88. Masaki T. Historical review: Endothelin. Trends Pharmacol Sci 2004;25:219-24.
89. Fagan KA, McMurtry IF, Rodman DM. Role of endothelin-1 in lung disease. Respir Res 2001;2:90-101.
90. Spinella F, Rosano L, Di Castro V, Natali PG, Bagnato A. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1α in ovarian carcinoma cells. J Biol Chem 2002;277:27850-5.
91. Okuda Y, Tsurumaru K, Suzuki S, et al. Hypoxia and endothelin-1 induce VEGF production in human vascular smooth muscle cells. Life Sci 1998;63:477-84.
92. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3:110-6.
93. Zonnenberg BA, Groenewegen G, Janus TJ, et al. Phase I dose-escalation study of the safety and pharmacokinetics of Atrasentan: an endothelin receptor antagonist for refractory prostate cancer. Clin Cancer Res 2003;9:2965-72.
94. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with Atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:679-89.
95. Steeg PS, Ouatas T, Halverson D, Palmieri D, Salerno M. Metastasis suppressor genes: basic biology and potential clinical use. Clin Breast Cancer 2003;4:51-62.
96. Welch DR. Microarrays bring new insights into understanding of breast cancer metastasis to bone. Breast Cancer Res 2004;6:61-4.